Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Equity Average (2020 - 2023)

Terns Pharmaceuticals' Equity Average history spans 4 years, with the latest figure at $266.3 million for Q3 2023.

  • For Q3 2023, Equity Average rose 65.96% year-over-year to $266.3 million; the TTM value through Sep 2023 reached $266.3 million, up 65.96%, while the annual FY2022 figure was $218.6 million, 920.13% up from the prior year.
  • Equity Average reached $266.3 million in Q3 2023 per TERN's latest filing, down from $280.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $282.3 million in Q1 2023 to a low of -$118.6 million in Q4 2020.
  • Average Equity Average over 4 years is $124.6 million, with a median of $163.3 million recorded in 2021.
  • The largest YoY upside for Equity Average was 325.87% in 2022 against a maximum downside of 23.0% in 2022.
  • A 4-year view of Equity Average shows it stood at -$118.6 million in 2020, then surged by 240.13% to $166.2 million in 2021, then skyrocketed by 38.55% to $230.3 million in 2022, then grew by 15.62% to $266.3 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Equity Average are $266.3 million (Q3 2023), $280.9 million (Q2 2023), and $282.3 million (Q1 2023).